TY  - JOUR
T1  - Nötropenik Kanser Hastalarından İzole Edilen Bakteriyel Ajanların İmipenem Duyarlılıkları
TT  - Susceptibilities of Bacterial Agents Isolated from Neutropenic Cancer Patients to Imipenem
AU  - Balıkçı, Erdener
AU  - Ayyıldız, M. Orhan
AU  - Tiftik, Naci
AU  - Şit, Dede
AU  - Mete, Ömer
AU  - Yazanel, Orhan
PY  - 1997
DA  - January
Y2  - 1997
JF  - Acta Medica Nicomedia
JO  - Acta Med Nicomedia
PB  - Kocaeli Üniversitesi
WT  - DergiPark
SN  - 2717-8994
SP  - 36
EP  - 37
VL  - 2
IS  - 1
LA  - tr
AB  - Hematoloji kliniğindetakip edilen nötropenik kanser hastalarından izole edilen çeşitli bakteriyelajanların imipeneme duyarlılıkları araştırıldı. İzole edilen toplam 56bakteriyel etkenin duyarlılık işlemleri agar-disk diffüzyon metoduylagerçekleştirildi. Etkenlerin 16’sı E. Coli, 10’u Pseudomonas spp, 12’siEnterobacter spp, 5’i Proteus spp, 5’i Klebsiella, 8’i Stafilokok olarak tespitedildi. Bu etkenlerin imipeneme duyarlılıkları sırasıyla 16 E. Coli suşunun13’ünde (%81,2), 10 Pseudomonas suşunun 8’inde (%80), 12 Enterobacter suşunun10’unda (%83,3), 5 Proteus suşunun 4’ünde (%80), 5 Klebsiella suşunun 3’ünde(%60), 8 Stafilokok suşunun 6’sında (%75) olarak bulundu.Sonuç olarak imipenemin,nötropenik kanser hastalarındaki bakteriyel ajanlara karşı önemli orandaduyarlılığı olan bir antibakteriyel olduğu gözlendi.
KW  - Nötropeni
KW  - İmipenem
N2  - Susceptibilitiesof various bacterial agents to imipenem isolated from neutropenic cancer patientsfollowed in the department of Hematology were investigated. Susceptibilityprocedures of totally 56 isolated bacterial agents were carried out byagar-disc diffusion method. Of the agents ,16 were found as E. Coli, 10 asPseudomonos spp, 12 as Enterobacter spp, 5 as Proteus spp, 5 as Klebsiella, and8 as Staphyloccocus. The susceptibility of these agents to Imıpenem wasidentified in 13 of 16 E. Coli strain (81.2%), 8 of 10 Pseudomonas strain (80%),10 of 12 Enterobacter strain (83.3%), 4 of 5 Proteus strain (80%), 3 of 5Klebsiella strain (60%) and 6 of 8 Staphyloccocus strain (75%).Consequently, itwas observed that Imipenem is an antibacterial agent that has significantefficacy against bacterial agents in neutropenic cancer patients.
CR  - Barza M. Imipenem: First of a new class of β-lactam antibiotics. Ann Intern Med. 1985;103:552-560.
CR  - Bauer AW, Kirby WMM, Scherris JC, Turck M. Antibiotic susceptibility testing by a standardized single method. Am J Clin Path. 1986;45:493-496.
CR  - Bodey GP. Antibiotics in patients with neutropenia. Arch Intern Med. 1984;144(9):1845-1851. doi:10.1001/archinte.1984.00350210173029
CR  - Bodey GP, Alvarez ME, Jones PG et al. Imipenem-cilastatin as initial therapy for febrile cancer patients. Antimicrob Agents Chemother. 1986;30(2):211-214. doi:10.1128/aac.30.2.211
CR  - Gaynes RP, Culver DH. Resistance to imipenem among selected Gram negative bacilli in the United States. Infect Control Hosp Epidemiol. 1992;13(1):10-14. doi:10.1086/646417
CR  - Kahan FM, Krupp H, Sundeluf JG, Birnbaum J. Thienamycin: development of imipenem- cilastatin. J Antimicrob Chemother. 1983;12:1-35.
CR  - Kocabeyoğlu Ö, Koşan E, Birinci İ, Kanmaz M, Yılmaz M. İmipenemin çeşitli bakteri suşlarına etkinliğinin mikrodilüsyon yöntemiyle araştırılması. ANKEM Derg. 1994;8(1):36-39.
CR  - National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing. Fourth Information Supplement. NCCLS Document M 100-S4. NCCLS, Villanova, PA, USA; 1992.
CR  - Neu HC, Labthavikul P. Comparative in vitro activity of N-formimidoyl thienamycin against gram positive and gram negative aerobic and anerobic species and its beta-lactamase stability. Antimicrob Agents Chemother. 1982;21(1):180-187.
CR  - Schimpff S, Satterlee W, Young VM, et al. Empiric therapy with Carbenicilin and gentamisin for febrile patients with cancer and granlocytopenia. N Engl J Med. 1971;284(19):1061-1065.
CR  - Watanabe X Hirumu R, Katsu K. Comparative in-vitro activities of newer cephalosporins cefclidin, cefepime and cefpirome against ceftazdime or imipenem rezistant Pseudomonas aerugmosa.  J Antimicrob Chemother. 1992;30(5):633-641.
UR  - https://dergipark.org.tr/tr/pub/actamednicomedia/issue//663111
L1  - https://dergipark.org.tr/tr/download/article-file/895932
ER  -